KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.

Wenyun GuoSongling LiYifei QianLinfeng LiFan WangYu TongQianyu LiZijun ZhuWei-Qiang GaoYanfeng Liu

Published in: Clinical and translational medicine (2023)

Our findings revealed that KDM6A promoted HCC progression by activating FGFR4 expression and may be an essential molecule for influencing the efficacy of lenvatinib in HCC therapy.

Keyphrases

poor prognosis
binding protein
signaling pathway
long non coding rna
stem cells
mesenchymal stem cells
bone marrow